lyophilisation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-09 and is reviewed periodically as new material appears.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
=== Legal status === The FDA issued the approval of escitalopram for major depression in August 2002, and for generalized anxiety disorder in December 2003. In May 2006, the FDA approved a generic version of escitalopram by Teva. In July 2006, the U.S. District Court of Delaware decided in favor of Lundbeck regarding a patent infringement dispute and ruled the patent on escitalopram valid. In 2006, Forest Laboratories was granted an 828-day (2 years and 3 months) extension on its US patent for escitalopram. This pushed the patent expiration date from 7 December 2009, to 14 September 2011. Together with the 6-month pediatric exclusivity, the final expiration date was 14 March 2012.
=== Banlieue Triste (2018–2020) === Hangman's Chair's fifth album, Banlieue Triste (lit. 'Sad Suburb'), was released in March 2018 through Music Fear Satan. The album features two guest contributions: one from Marc De Backer of Mucky Pup on "Sidi Bel Abbes", and the other from French synthwave musician Perturbator on "Tired Eyes". Banlieue Triste spawned a music video for "Naive" released in April 2018, starring French actor Nicolas Duvauchelle. Duvauchelle, who was part of the Parisian hardcore scene with his band Cry Havoc and is a longtime friend of Hangman's Chair, stated: "I didn't hesitate for a second. They're such a negative band, and I love it". He played his part as a volunteer. In May, a music video for "Touch the Razor", produced by 12jours (lit. '12days'), was released on Vimeo. On 15 June, they performed at Download Festival France at the Brétigny-sur-Orge Air Base 217.
=== Journalist spying scandal === In October 2022, Forbes reported that a team at ByteDance planned to surveil certain US citizens for undisclosed reasons. TikTok said that the tracking method suggested by the report would not be feasible because precise GPS information is not collected by the platform. In December 2022, ByteDance confirmed after internal investigation that the data of two journalists and their close contacts had been accessed by its employees from China and the United States. It was intended to uncover sources of leaks who might have met with the journalists from Forbes and the Financial Times. The data included IP addresses, which can be used to approximate a user's location. ByteDance stated that it fired four employees in response. The incident is being investigated by the US Department of Justice and FBI. The US Attorney for the Eastern District of Virginia reportedly subpoenaed information from ByteDance regarding its surveillance of journalists on TikTok. In December 2023, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party inquired the FBI about the status of the case.
Sources: en.wikipedia.org
== Dorsopathies (720–724) == 720 Ankylosing spondylitis and other inflammatory spondylopathies 720.0 Ankylosing spondylitis 720.1 Spinal enthesopathy 720.2 Sacroiliitis 721 Spondylosis and allied disorders 721.0 Cervical spondylosis w/o myelopathy 721.1 Cervical spondylosis, w/myelopathy 721.2 Thoracic spondylosis w/o myelopathy 721.3 Lumbosacral spondylosis w/o myelopathy 721.4 Thoracic or lumbar spondylosis w/ myelopathy 721.5 Kissing spine 721.6 Ankylosing vertebral hyperostosis 721.7 Traumatic spondylopathy 722 Intervertebral disc disorders 722.0 Displacement cervical intervertebral disc 722.1 Lumbar disc displacement w/o myelopathy 722.2 Degeneration of intervertebral disc site unspecified 722.3 Schmorl's nodes 722.4 Degenerative disc disease, cervical 722.5 Degeneration of thoracic or lumbar intervertebral disc 722.51 Degenerative disc disease, thoracic 722.52 Degenerative disc disease, lumbar 722.6 Degeneration of intervertebral disc, site unspecified Degenerative disc disease 722.7 Intervertebral disc disorder with myelopathy 722.8 Postlaminectomy syndrome 723 Other disorders of cervical region 723.0 Spinal stenosis in cervical region 723.1 Cervicalgia 723.2 Cervicocranial syndrome 723.3 Cervicobrachial syndrome (diffuse) 723.4 Brachial neuritis or radiculitis nos 723.5 Torticollis unspecified 723.6 Panniculitis specified as affecting neck 723.7 Ossification of posterior longitudinal ligament in cervical region 724 Other and unspecified disorders of back 724.0 Spinal stenosis, other than cervical 724.1 Pain in thoracic spine 724.2 Lumbago 724.3 Sciatica 724.4 Back pain w/ radiation, unspec. 724.5 Backache, unspecified 724.6 Disorders of sacrum 724.7 Disorders of coccyx 724.79 Coccygodynia 724.8 Other symptoms referable to back
The human penis is thicker than that of any other primate, both in absolute terms and relative to the rest of the body. Early research, based on inaccurate measurements, concluded that the human penis was also longer. In fact, the penis of the common chimpanzee is no shorter than in humans, averaging 14.4 cm (5.7 inches), and some other primates have comparable penis sizes relative to their body weight. The evolutionary reasons for the increased thickness have not been established. One explanation is that thicker penises are an adaptation to a corresponding increase in vaginal size. The vaginal canal is believed to have expanded in humans to accommodate the larger size of a newborn's skull. Women may then have sexually selected men with penises large enough to fit their vagina, to provide sexual stimulation and ensure ejaculation. Other evolutionary hypotheses to explain humans' relatively large penis length and girth include a sperm competition hypothesis and a mate competition hypothesis. The sperm competition hypothesis does not have much support as in other mammals where sperm competition is present, larger testes evolve, not larger penises. The mate competition hypothesis involves the prediction that a human with a larger penis would be able to displace the sperm of another. Studies have found that larger penises do not displace other sperm more effectively than smaller penises, but rather longer penises may ejaculate sperm inside the vagina in places that would be harder for a following penis to displace.
Governor King had been requesting a replacement, for at least a year. In 1805, Governor William Bligh was appointed. Although the economy had developed and diversified somewhat by 1806, Bligh arrived determined to bring the Corps, and especially John Macarthur, to heel, and stop their trading in rum. This led to the Rum Rebellion, the deposing of Bligh, and the eventual recall of the New South Wales Corps. In 1808, the New South Wales Corps was renamed the 102d Regiment of Foot. Having arrived in the colony in December 1809 with the 73rd Regiment of Foot, which was to take over from the 102d Regiment of Foot, Governor Lachlan Macquarie was able to control the rum trade more effectively, introducing and enforcing a licensing system. Due to the lack of currency, he was still forced to pay for public works in rum. The construction of Sydney Hospital was entirely funded by granting a monopoly on the import of rum to the contractors, who were the merchants Alexander Riley and Garnham Blaxcell. The colonial surgeon D'Arcy Wentworth, and troops were used to prohibit the landing of rum anywhere but at the hospital dock. A few of the officers and long-serving privates in the 102d Regiment were transferred to Macquarie's 73rd regiment, bringing it up to near full strength. About 100 veterans and invalids were retained for garrison duty in New South Wales.
==== Alzheimer's disease ==== Decreased expression of ChAT is one of the hallmarks of Alzheimer's disease. Patients with Alzheimer's disease show a 30 to 90% reduction in activity in several regions of the brain, including the temporal lobe, the parietal lobe and the frontal lobe. However, ChAT deficiency is not believed to be the main cause of this disease.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.